[A19-57] Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2019
Project no.:
A19-57
Commission:
Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer
Without prior chemotherapy for metastatic breast cancer: indication of considerable added benefit; with prior chemotherapy for metastatic breast cancer: hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-56 | Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-36 | Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-97 | Olaparib (breast cancer) - Addendum to Commission A19-57 | Commission completed |
| G15-05 | Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A20-115 | Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-106 | Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-111 | Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |